✦ LIBER ✦

CAST: Implications for drug development

✍ Scribed by Woosley, Raymond L

Book ID: 109844884
Publisher: Nature Publishing Group
Year: 1990
Tongue: English
Weight: 340 KB
Volume: 47
Category: Article
ISSN: 0009-9236
DOI: 10.1038/clpt.1990.75

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic Protein–Drug Interactions an

Therapeutic Protein–Drug Interactions and Implications for Drug Development

✍ Huang, S-M; Zhao, H; Lee, J-I; Reynolds, K; Zhang, L; Temple, R; Lesko, L J 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 142 KB

Drug development for cancer: Implication

Drug development for cancer: Implications for chemical modifiers

✍ Bruce A. Chabner; Dale Shoemaker 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 381 KB

Toxicity of antiretroviral therapy and i

Toxicity of antiretroviral therapy and implications for drug development

✍ Carr, Andrew 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 404 KB

BRAF, a target in melanoma : Implication

BRAF, a target in melanoma : Implications for solid tumor drug development

✍ Keith T. Flaherty; Grant McArthur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract The successful translation of therapies targeting signal‐transduction pathways that are activated by oncogenes has provided a model for molecularly targeted therapy, and the identification of mutations in v‐raf murine sarcoma viral oncogene homolog B1 (__BRAF__), a serine/threonine kina

Emerging molecular classification in ren

Emerging molecular classification in renal cell carcinoma: implications for drug development

✍ Kathryn E. Hacker; W. Kimryn Rathmell 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 176 KB

Predicting microstructure development du

Predicting microstructure development during casting of drug-eluting coatings

✍ David M. Saylor; Jonathan E. Guyer; Daniel Wheeler; James A. Warren 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 830 KB

We have devised a novel diffuse interface formulation to model the development of chemical and physical inhomogeneities, i.e. microstructure, during the process of casting drug-eluting coatings. These inhomogeneities, which depend on the coating constituents and manufacturing conditions, can have a